PacificGMP  (San Diego, CA) and Pacific Biopharma Group (San Diego, CA) have signed a  merger agreement to develop a cGMP (current good manufacturing practices)  biologics contract manufacturing organization (CMO) in Taizhou, China. At  approximately 200,000 square feet, the Taizhou-based CMO, called China  Quantitative Biomedicine (CQB), will be one of the largest single-use  biomanufacturing facilities in the US or China. Construction of the facility in  Taizhou is expected to be completed in August 2008, with internal construction  and equipment installation expected to be completed by the end of 2008.

Under  conditions of the merger agreement, PacificGMP will receive funds to expand its  operation in San Diego and assist in the development of the Taizhou facility  and preparations for FDA and EMEA audits. The new facility is a showcase  laboratory and part of a new biopharmaceutical park called China Medical City  (CMC). CMC is a 12-km2-life sciences-focused science park located in  Jiangsu Province, the leading pharmaceutical manufacturing province in China.  The facility will be modeled after PacificGMP’s San Diego facility that uses  single-use technology throughout the biomanufacturing process. Single-use  technology has fewer system requirements than traditional reusable  biomanufacturing systems and significantly reduces the cost of product  manufacturing.

News

PacificGMP (San Diego, CA) and Pacific Biopharma Group (San Diego, CA) have signed a merger agreement to develop a cGMP (current good manufacturing practices) biologics contract manufacturing organization (CMO) in Taizhou, China.